Tuesday, July 21, 2020

India's Glenmark makes FabiFlu to treat Corona Virus patients

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19


Source: IndiaNewsTV.com

More here: https://tinyurl.com/y8g2jyyh

What is FabiFlu?

According to Glenmark, India:

•It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, the drug firm said.

•Available Through Retail & Hospital Channels

•200 Mg Tablet, 34 Tablets in A Strip, ₹103/Tablet ..Strip MRP ₹3500

•The company is producing the active pharmaceutical ingredients (API) for the product at its Ankleshwar plant, while the formulation is being manufactured at its Baddi plant.

•Finally A Good News In Fight Against COVID19. It's Launched Under Brand Name FabiFlu.

•FabiFlu(Favipiravir ) has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases.

Who makes it in India?

Glenmark launches Covid-19 drug at Rs 103 per tablet.

https://en.wikipedia.org/wiki/Glenmark_Pharmaceuticals

Who made the original Favipiravir?

FabiFlu is same as Avigan in Japan. Avigan was developed in 2014 by Fujifilm Toyama Chemical, a unit of Fujifilm Holdings.

According to FujiFilm spokesperson,

“Avigan is a viral RNA polymerase inhibitor, with a new mechanism of action that inhibits viral gene replication within infected cells,”.

Japan is testing Avigan in 43 countries.

More here: https://tinyurl.com/yaek2jxv

No comments:

Post a Comment